Jefferson University Hospitals

Physician Profile

Scott Waldman, MD

Academic Title: Professor
Chair, Pharmacology & Experimental Therapeutics

Specialties
Clinical Pharmacology (Not Accepting New Patients)

Office Locations

Philadelphia
132 S. 10th Street
Main Bldg., Ste 1170
Philadelphia PA 19107
Phone: (215) 955-6086
Fax: (215) 955-5681

Board Certifications

  • Internal Medicine
  • Clinical Pharmacology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital

Education

  • Stanford University School of Medicine, Medical School

Internship

  • Stanford University Hospital

Residency

  • Stanford University Hospital

Recent Publications

GUCY2C signaling opposes the acute radiation-induced GI syndrome

ST-producing E. Coli oppose carcinogen-induced colorectal tumorigenesis in mice

Peer Review Certifies Quality and Innovation in Clinical Pharmacology & Therapeutics

Bioactivity of oral linaclotide in human colorectum for cancer chemoprevention

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer

Prime-boost immunization eliminates metastatic colorectal cancer by producing high-Avidity effector CD8+ T cells

Clinical Pharmacology & Therapeutics: Past, Present, and Future

Cardiopoietic cell therapy for advanced ischaemic heart failure: Results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial

EXECUTIVE INTERVIEW - Viral gene: Protein-targeting cancer vaccine could boost survival rates

Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis

Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope

A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients

Guanylyl cyclase C signaling axis and colon cancer prevention

Guanylyl cyclase C hormone axis at the intersection of obesity and colorectal cancer

Targeting guanylate cyclase C in colorectal cancer: Where are we now?

GUCY2C ligand replacement to prevent colorectal cancer

Big data transforms discoveryutilization therapeutics continuum

Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis

Bioinnovation Enterprise: An Engine Driving Breakthrough Therapies

Intestinal enteroids model guanylate cyclase C-dependent secretion induced by heat-stable enterotoxins